3.40

6.34% -0.23

Opthea Limited ADR (OPT)

Overview News Price History Discussions Forecast Stock Split

Opthea Limited ADR stock is currently priced at $3.40, with a 24-hour trading volume of 2,897. It has seen a -6.34% decreased in the last 24 hours and a -8.36% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $3.57 pivot point. If it approaches the $3.34 support level, significant changes may occur.

Previous Close:

$3.63

Open:

$3.5

24h Volume:

2,897

Market Cap:

$281.69M

Revenue:

$117.10K

Net Income/Loss:

$-161.61M

P/E Ratio:

-1.4002

EPS:

-2.4283

Net Cash Flow:

1W Performance:

+3.03%

1M Performance:

-8.36%

6M Performance:

+112.50%

1Y Performance:

-11.45%

1D Range:

$3.40

$3.50

52W Range:

$1.60

$4.42

Opthea Limited ADR Stock (OPT) Company Profile

Name

Opthea Limited ADR

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

61 3 9826 0399

Address

650 Chapel Street, Suite 0403 Level 4, South Yarra

Employee

Twitter

Next Earnings Date

Latest SEC Filings

OPT's Discussions on Twitter

Opthea Limited ADR Stock (OPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-08-22	Initiated	H.C. Wainwright	Buy
Apr-26-22	Initiated	SVB Leerink	Outperform
Nov-17-20	Initiated	Citigroup	Buy
Nov-11-20	Initiated	Oppenheimer	Outperform
Nov-11-20	Initiated	SVB Leerink	Outperform
Nov-11-20	Initiated	Truist	Buy

View All

Opthea Limited ADR Stock (OPT) Latest News

Optiva and GDi Announce Strategic Partnership to Deliver Integrated BSS and OSS Solutions

GlobeNewswire Inc.

Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024

GlobeNewswire Inc.

Optiva Inc. Reports Fourth Quarter 2023 Financial Results

GlobeNewswire Inc.

Opthea Limited ADR Stock (OPT) Financials Data

Opthea Limited ADR (OPT) Revenue 2024

OPT reported a revenue (TTM) of $117.10 thousand for the quarter ending December 31, 2023, a +239.07% rise year-over-year.

Opthea Limited ADR (OPT) Net Income 2024

OPT net income (TTM) was -$161.61 million for the quarter ending December 31, 2023, a -181.90% decrease year-over-year.

Opthea Limited ADR (OPT) Earnings per Share 2024

OPT earnings per share (TTM) was -$2.4059 for the quarter ending December 31, 2023, a -101.79% decline year-over-year.

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.